Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patients
Modus Therapeutics is going to launch a Phase 1 clinical study in the United States to evaluate the potential of its lead candidate sevuparin for the treatment of sickle cell disease (SCD).
In the trial, the company will broaden the clinical scope and usefulness of sevuparin to treat sickle cell disease by testing its safety when administrated subcutaneously (under the skin).
This follows the acceptance by the U.S Food and Drug Administration (FDA) of an investigational new drug (IND) application for sevuparin.
Modus Therapeutics is currently evaluating the therapeutic activity of sevuparin to manage painful crisis, also known as acute vaso-occlusive crisis (VOC), in patients with sickle cell disease in an ongoing Phase 2 study (NCT02515838).
+myBinderRelated Content
-
Unanticipated consequences identified after implementation of a pediatric emergency department (PED)-based intranasa...Background: The 2014 National Heart Lun...
-
Sickle Cell Anemia Treatment & ManagementThe National Institutes of Health advise...
-
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
Vaso-Occlusive Pain Linked to Menstruation in Some Patients, Study FindsAcute vaso-occlusive pain is associated ...
-
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
-
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell TrialSancilio Pharmaceuticals says its invest...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.